Recruiting PHASE2 Insomnia Chronic

Tests treatment safety and results for Insomnia Chronic

Official title Efficacy of Trazodone to Treat Insomnia in Older Adults (TRADITION Study)

ClinicalTrials.gov ID: NCT06983080

What this study is testing

What is Trazodone 25 mg?

Trazodone 25 mg is an investigational medicine, being studied as a potential treatment for insomnia chronic.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This study aims to evaluate how effective trazodone is in treating insomnia in adults aged 65 years and older. The main question it aims to answer is : \- Is trazodone more effective than a placebo in reducing the severity of insomnia symptoms in older adults?
  • Phase 2: a mid-size study of how well it works
  • You might receive a placebo (an inactive treatment) instead of the study drug.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 65 and older

You may be able to join if

  • Individuals aged 65 or older in an outpatient setting
  • Insomnia according to the criteria of the ICSD-3R

You likely can't join if

  • Contraindication to trazodone (hypersensitivity)
  • Presence of a ventricular cardiac arrhythmia (e.g., torsades de pointes)
  • Recent myocardial infarction (\< 6 months)
  • Substances that may alter sleep (hypnotics or any other medication intended to induce sleep, such as mirtazapine or quetiapine, corticosteroids...
  • Active, unstable psychiatric disorder
  • Initiation or titration of an antidepressant within the past 6 months
See the full eligibility criteria
Who can join
  • Individuals aged 65 or older in an outpatient setting
  • Insomnia according to the criteria of the ICSD-3R
What rules you out
  • Contraindication to trazodone (hypersensitivity)
  • Presence of a ventricular cardiac arrhythmia (e.g., torsades de pointes)
  • Recent myocardial infarction (\< 6 months)
  • Substances that may alter sleep (hypnotics or any other medication intended to induce sleep, such as mirtazapine or quetiapine, corticosteroids, melatonin, psychostimulant drugs)
  • Active, unstable psychiatric disorder
  • Initiation or titration of an antidepressant within the past 6 months
  • Cognitive-behavioral therapy ongoing or planned during the study period
  • Major neurocognitive disorder (NCD) moderate or severe, or other cognitive disorders that may prevent the participant from being able to participate in the study, according to the judgment of the evaluating physician
  • Parkinson's disease
  • Priapism
  • Known angle-closure glaucoma
  • Symptomatic restless leg syndrome \> 3 times per week
  • QTc interval \> 500 ms
  • Parasomnias, dyssomnias other than insomnia
  • Severe sleep apnea with AHI \> 30 without CPAP treatment
  • Use of a monoamine oxidase inhibitor
  • Use of a strong CYP 3A4 inducer or inhibitor
  • Hospitalized individuals
  • Seizure within the past 6 months
  • History of orthostatic hypotension
  • History of delirium within the last 6 months
  • Consumption of \> 14 alcoholic drinks per day or use of alcohol to induce sleep.

The study team makes the final eligibility decision.

Where it's taking place

  • Montreal, Quebec, Canada

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 65 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Montreal, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.